|
|
Home > Healthcare > Biotechnology > Genetics & Genomics
Opportunities for the European Mass Spectrometry Market in Clinical Applications
|
| Published Date:
February 2008
Published By:
Frost & Sullivan
Page Count:
115
Order Code:
R1-6328
|
|
|
|
This Frost & Sullivan research service titled Opportunities for the European Mass Spectrometry Markets in Clinical Applications provides an overview of the mass spectrometry markets in Europe, along with their scope in clinical applications and potential revenues. A complete analysis of key drivers, restraints and trends in the market is also provided. Strategic solutions necessary to gain advantage in this growing market are also detailed. Also detailed are the revenues generated by each instrument as well as within regions.
This analysis is available through our Drug Discovery Technologies Growth Partnership Services programme. With this programme, clients receive industry-leading market research such as this, along with technical and econometric data and many interactive features including Analyst Inquiry Time and Client Councils.
Market Overview
Mass Spectrometry Gains Increasing Importance in Clinical Applications as a Key Identification Tool
Over the span of the century, applications of mass spectrometry (MS) have expanded significantly. The primary focus of these applications has been clinical and molecular research. The elucidation of the human genetic code has created a portal through which the human body can be more accurately explored. In providing a powerful tool for this ongoing research, the MS industry has gained considerable importance. Aware of the technological potential within this steadily growing market, funding from public and private sources have soared. There is now a rising interest in integrating technologies. For instance, bio-informatics and protein biochip technologies coupled with MS are expanding in a phenomenal way across European markets. This is primarily due to the clarity and quantification of the results obtained. MS has been the primary identification tool for today’s researchers in analysing proteins, peptides, carbohydrates, DNA, drugs, and many other biologically relevant molecules.
"The European MS markets will be driven by the ongoing implementation of competitive strategies, including the hybridisation of existing spectrometric techniques (Tandem MS) for accurate throughput results," notes the analyst of this research. "In the clinical diagnostic sector, areas such as biomarker identification and automated genotyping have exhibited a phenomenal increase in the usage of hybrid MS instruments." Currently, Tandem MS is the most powerful tool in the identification of peptides and proteins for proteomics and drug discovery research. With higher resolution and accuracy standards being of prime importance for researchers and physicians, hybrid MS systems offer a potential strategy to attain greater market presence.
Technology Advances, Widening Application Base Bolster Prospects of MS Markets
Even though the European MS markets have reached a stage of maturity, they are still highly competitive with technological advances, mounting awareness of their role in clinical diagnostics and a widening application base set to promote the uptake of MS instruments. Manufacturers have to anticipate future market trends and the requirements of researchers and introduce solutions accordingly. "New applications applying mass spectrometry as an analytical tool continue to emerge, leading to expanded market potential and growth," observes the analyst. "With novel technologies being introduced into the global analytical instrumentation industry, more powerful and faster mass spectrometers catering to a wide range of applications have started attracting laboratory researchers and research-oriented organisations."
To succeed in this market, companies should form favourable partnerships, alliances or undertake mergers and acquisitions. Owing to the rising R&D investments in life sciences and bioinstrumentation, market participants stand to benefit by merging or partnering with other companies, thereby reducing their expenditure. Other advantages of this strategy include an exchange of basic technology, building a broader customer base together with a stronger sales and distribution network.
|
Similar Products
• Biotechnology Sector
Published Nov 2008 by First Research, Inc.
• Key Genetic Technologies Market Research Bundle (SNPs, Gene Expression Profiling, DNA Sequencing and Biochips)
Published Nov 2008 by Kalorama Information
• Genetics Bundle
Published Nov 2008 by Trimark Publications
• Plunkett's Health Care Technologies Overview 2009 (Summary)
Published Oct 2008 by Plunkett Research, Ltd.
• GPCRs: Dawn of a New Era?
Published Oct 2008 by CHI Insight Pharma Reports
• How to Integrate Personalized Medicine into Business Strategies
Published Sep 2008 by Decision Resources
• U.S. Nucleic Acid Purification and Isolation Markets
Published Sep 2008 by Frost & Sullivan
• The 2009-2014 World Outlook for Genotyping Analysis Services
Published Sep 2008 by Icon Group International, Inc.
• The 2009-2014 World Outlook for Genetic Analysis Services
Published Sep 2008 by Icon Group International, Inc.
• The 2009-2014 World Outlook for Gene Expression Services
Published Sep 2008 by Icon Group International, Inc.
|
|
|
|
0 items
